JP2019532657A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2019532657A5 JP2019532657A5 JP2019522512A JP2019522512A JP2019532657A5 JP 2019532657 A5 JP2019532657 A5 JP 2019532657A5 JP 2019522512 A JP2019522512 A JP 2019522512A JP 2019522512 A JP2019522512 A JP 2019522512A JP 2019532657 A5 JP2019532657 A5 JP 2019532657A5
- Authority
- JP
- Japan
- Prior art keywords
- item
- polypeptide
- lnp
- composition
- group
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000000203 mixture Substances 0.000 claims description 121
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 119
- 229920001184 polypeptide Polymers 0.000 claims description 103
- 102000004196 processed proteins & peptides Human genes 0.000 claims description 103
- 239000000427 antigen Substances 0.000 claims description 55
- 102000036639 antigens Human genes 0.000 claims description 55
- 108091007433 antigens Proteins 0.000 claims description 55
- 150000002632 lipids Chemical class 0.000 claims description 53
- 230000028993 immune response Effects 0.000 claims description 51
- 108020004999 messenger RNA Proteins 0.000 claims description 50
- 239000002105 nanoparticle Substances 0.000 claims description 48
- 229940076838 Immune checkpoint inhibitor Drugs 0.000 claims description 32
- 239000012274 immune-checkpoint protein inhibitor Substances 0.000 claims description 32
- 239000003937 drug carrier Substances 0.000 claims description 25
- 238000000034 method Methods 0.000 claims description 23
- -1 TAK-TAB1 Proteins 0.000 claims description 20
- 101710196623 Stimulator of interferon genes protein Proteins 0.000 claims description 15
- 230000004936 stimulating effect Effects 0.000 claims description 15
- 230000002708 enhancing effect Effects 0.000 claims description 14
- 108010077432 Myeloid Differentiation Factor 88 Proteins 0.000 claims description 13
- 102000010168 Myeloid Differentiation Factor 88 Human genes 0.000 claims description 13
- 101001011382 Homo sapiens Interferon regulatory factor 3 Proteins 0.000 claims description 12
- 101001032342 Homo sapiens Interferon regulatory factor 7 Proteins 0.000 claims description 12
- 230000016396 cytokine production Effects 0.000 claims description 12
- 101100508533 Drosophila melanogaster IKKbeta gene Proteins 0.000 claims description 11
- 101001109145 Homo sapiens Receptor-interacting serine/threonine-protein kinase 1 Proteins 0.000 claims description 11
- 101000595554 Homo sapiens TIR domain-containing adapter molecule 2 Proteins 0.000 claims description 11
- 101000649115 Homo sapiens Translocating chain-associated membrane protein 1 Proteins 0.000 claims description 11
- 102100022501 Receptor-interacting serine/threonine-protein kinase 1 Human genes 0.000 claims description 11
- 102100027965 Translocating chain-associated membrane protein 1 Human genes 0.000 claims description 11
- 101000665442 Homo sapiens Serine/threonine-protein kinase TBK1 Proteins 0.000 claims description 9
- 102100029843 Interferon regulatory factor 3 Human genes 0.000 claims description 9
- 102100038192 Serine/threonine-protein kinase TBK1 Human genes 0.000 claims description 9
- 239000012634 fragment Substances 0.000 claims description 9
- 102100038070 Interferon regulatory factor 7 Human genes 0.000 claims description 8
- 206010028980 Neoplasm Diseases 0.000 claims description 8
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 claims description 8
- 201000011510 cancer Diseases 0.000 claims description 7
- 108010074708 B7-H1 Antigen Proteins 0.000 claims description 6
- 102100025752 CASP8 and FADD-like apoptosis regulator Human genes 0.000 claims description 6
- 102100039498 Cytotoxic T-lymphocyte protein 4 Human genes 0.000 claims description 6
- 101000834898 Homo sapiens Alpha-synuclein Proteins 0.000 claims description 6
- 101000889276 Homo sapiens Cytotoxic T-lymphocyte protein 4 Proteins 0.000 claims description 6
- 101000598002 Homo sapiens Interferon regulatory factor 1 Proteins 0.000 claims description 6
- 101001032345 Homo sapiens Interferon regulatory factor 8 Proteins 0.000 claims description 6
- 101001011663 Homo sapiens Mixed lineage kinase domain-like protein Proteins 0.000 claims description 6
- 101000611936 Homo sapiens Programmed cell death protein 1 Proteins 0.000 claims description 6
- 101000652359 Homo sapiens Spermatogenesis-associated protein 2 Proteins 0.000 claims description 6
- 102100036981 Interferon regulatory factor 1 Human genes 0.000 claims description 6
- 102100038069 Interferon regulatory factor 8 Human genes 0.000 claims description 6
- 102100030177 Mixed lineage kinase domain-like protein Human genes 0.000 claims description 6
- 101710100501 CASP8 and FADD-like apoptosis regulator Proteins 0.000 claims description 5
- 108090000426 Caspase-1 Proteins 0.000 claims description 5
- 102100033189 Diablo IAP-binding mitochondrial protein Human genes 0.000 claims description 5
- 101000871228 Homo sapiens Diablo IAP-binding mitochondrial protein Proteins 0.000 claims description 5
- 101001011442 Homo sapiens Interferon regulatory factor 5 Proteins 0.000 claims description 5
- 101001032341 Homo sapiens Interferon regulatory factor 9 Proteins 0.000 claims description 5
- 101000643024 Homo sapiens Stimulator of interferon genes protein Proteins 0.000 claims description 5
- 102100030131 Interferon regulatory factor 5 Human genes 0.000 claims description 5
- 102100038251 Interferon regulatory factor 9 Human genes 0.000 claims description 5
- 101100452374 Mus musculus Ikbke gene Proteins 0.000 claims description 5
- 102000050022 human STING1 Human genes 0.000 claims description 5
- NRJAVPSFFCBXDT-HUESYALOSA-N 1,2-distearoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCCCCCCCCCCCC NRJAVPSFFCBXDT-HUESYALOSA-N 0.000 claims description 4
- 102100035904 Caspase-1 Human genes 0.000 claims description 4
- 235000012000 cholesterol Nutrition 0.000 claims description 4
- 239000008194 pharmaceutical composition Substances 0.000 claims description 4
- 229940045513 CTLA4 antagonist Drugs 0.000 claims description 3
- 102000004127 Cytokines Human genes 0.000 claims description 3
- 108090000695 Cytokines Proteins 0.000 claims description 3
- 229960003852 atezolizumab Drugs 0.000 claims description 3
- 229950002916 avelumab Drugs 0.000 claims description 3
- 229950009791 durvalumab Drugs 0.000 claims description 3
- 229960005386 ipilimumab Drugs 0.000 claims description 3
- 229960003301 nivolumab Drugs 0.000 claims description 3
- 229960002621 pembrolizumab Drugs 0.000 claims description 3
- 229950007217 tremelimumab Drugs 0.000 claims description 3
- 150000003904 phospholipids Chemical class 0.000 claims description 2
- 125000000217 alkyl group Chemical group 0.000 claims 15
- 125000003342 alkenyl group Chemical group 0.000 claims 12
- 150000001875 compounds Chemical class 0.000 claims 7
- 150000003839 salts Chemical class 0.000 claims 5
- 125000003118 aryl group Chemical group 0.000 claims 3
- 229910052799 carbon Inorganic materials 0.000 claims 3
- 125000001072 heteroaryl group Chemical group 0.000 claims 3
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical group [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 claims 2
- 102100024216 Programmed cell death 1 ligand 1 Human genes 0.000 claims 2
- 102100040678 Programmed cell death protein 1 Human genes 0.000 claims 2
- LNUFLCYMSVYYNW-ZPJMAFJPSA-N [(2r,3r,4s,5r,6r)-2-[(2r,3r,4s,5r,6r)-6-[(2r,3r,4s,5r,6r)-6-[(2r,3r,4s,5r,6r)-6-[[(3s,5s,8r,9s,10s,13r,14s,17r)-10,13-dimethyl-17-[(2r)-6-methylheptan-2-yl]-2,3,4,5,6,7,8,9,11,12,14,15,16,17-tetradecahydro-1h-cyclopenta[a]phenanthren-3-yl]oxy]-4,5-disulfo Chemical compound O([C@@H]1[C@@H](COS(O)(=O)=O)O[C@@H]([C@@H]([C@H]1OS(O)(=O)=O)OS(O)(=O)=O)O[C@@H]1[C@@H](COS(O)(=O)=O)O[C@@H]([C@@H]([C@H]1OS(O)(=O)=O)OS(O)(=O)=O)O[C@@H]1[C@@H](COS(O)(=O)=O)O[C@H]([C@@H]([C@H]1OS(O)(=O)=O)OS(O)(=O)=O)O[C@@H]1C[C@@H]2CC[C@H]3[C@@H]4CC[C@@H]([C@]4(CC[C@@H]3[C@@]2(C)CC1)C)[C@H](C)CCCC(C)C)[C@H]1O[C@H](COS(O)(=O)=O)[C@@H](OS(O)(=O)=O)[C@H](OS(O)(=O)=O)[C@H]1OS(O)(=O)=O LNUFLCYMSVYYNW-ZPJMAFJPSA-N 0.000 claims 2
- 125000000623 heterocyclic group Chemical group 0.000 claims 2
- 101000914211 Homo sapiens CASP8 and FADD-like apoptosis regulator Proteins 0.000 claims 1
- 101001011446 Homo sapiens Interferon regulatory factor 6 Proteins 0.000 claims 1
- 102100026720 Interferon beta Human genes 0.000 claims 1
- 102100030130 Interferon regulatory factor 6 Human genes 0.000 claims 1
- 108090000467 Interferon-beta Proteins 0.000 claims 1
- 101100335081 Mus musculus Flt3 gene Proteins 0.000 claims 1
- 102000001708 Protein Isoforms Human genes 0.000 claims 1
- 108010029485 Protein Isoforms Proteins 0.000 claims 1
- 108010044012 STAT1 Transcription Factor Proteins 0.000 claims 1
- 108010081691 STAT2 Transcription Factor Proteins 0.000 claims 1
- 102000004265 STAT2 Transcription Factor Human genes 0.000 claims 1
- 108010019992 STAT4 Transcription Factor Proteins 0.000 claims 1
- 102000005886 STAT4 Transcription Factor Human genes 0.000 claims 1
- 108010011005 STAT6 Transcription Factor Proteins 0.000 claims 1
- 102000013968 STAT6 Transcription Factor Human genes 0.000 claims 1
- 102100029904 Signal transducer and activator of transcription 1-alpha/beta Human genes 0.000 claims 1
- 125000003275 alpha amino acid group Chemical group 0.000 claims 1
- 125000002837 carbocyclic group Chemical group 0.000 claims 1
- 125000000592 heterocycloalkyl group Chemical group 0.000 claims 1
- 230000009851 immunogenic response Effects 0.000 claims 1
- 230000000091 immunopotentiator Effects 0.000 description 24
- 230000005867 T cell response Effects 0.000 description 18
- 210000001744 T-lymphocyte Anatomy 0.000 description 16
- 101000979342 Homo sapiens Nuclear factor NF-kappa-B p105 subunit Proteins 0.000 description 14
- 102100023050 Nuclear factor NF-kappa-B p105 subunit Human genes 0.000 description 14
- 108010014726 Interferon Type I Proteins 0.000 description 12
- 102000002227 Interferon Type I Human genes 0.000 description 12
- 230000015572 biosynthetic process Effects 0.000 description 12
- 102100023727 Mitochondrial antiviral-signaling protein Human genes 0.000 description 11
- 101710142315 Mitochondrial antiviral-signaling protein Proteins 0.000 description 11
- 239000003814 drug Substances 0.000 description 11
- 230000001404 mediated effect Effects 0.000 description 11
- 230000007112 pro inflammatory response Effects 0.000 description 11
- 230000004044 response Effects 0.000 description 11
- 101000852483 Homo sapiens Interleukin-1 receptor-associated kinase 1 Proteins 0.000 description 10
- 101000977771 Homo sapiens Interleukin-1 receptor-associated kinase 4 Proteins 0.000 description 10
- 102100036342 Interleukin-1 receptor-associated kinase 1 Human genes 0.000 description 10
- 102100023533 Interleukin-1 receptor-associated kinase 4 Human genes 0.000 description 10
- 102000003714 TNF receptor-associated factor 6 Human genes 0.000 description 10
- 108090000009 TNF receptor-associated factor 6 Proteins 0.000 description 10
- 102000014150 Interferons Human genes 0.000 description 9
- 108010050904 Interferons Proteins 0.000 description 9
- 229940079322 interferon Drugs 0.000 description 9
- 102000002689 Toll-like receptor Human genes 0.000 description 8
- 108020000411 Toll-like receptor Proteins 0.000 description 8
- 210000003719 b-lymphocyte Anatomy 0.000 description 8
- ZAYHVCMSTBRABG-UHFFFAOYSA-N 5-Methylcytidine Natural products O=C1N=C(N)C(C)=CN1C1C(O)C(O)C(CO)O1 ZAYHVCMSTBRABG-UHFFFAOYSA-N 0.000 description 7
- ZAYHVCMSTBRABG-JXOAFFINSA-N 5-methylcytidine Chemical compound O=C1N=C(N)C(C)=CN1[C@H]1[C@H](O)[C@H](O)[C@@H](CO)O1 ZAYHVCMSTBRABG-JXOAFFINSA-N 0.000 description 7
- 230000035772 mutation Effects 0.000 description 7
- ZXIATBNUWJBBGT-JXOAFFINSA-N 5-methoxyuridine Chemical compound O=C1NC(=O)C(OC)=CN1[C@H]1[C@H](O)[C@H](O)[C@@H](CO)O1 ZXIATBNUWJBBGT-JXOAFFINSA-N 0.000 description 6
- 102100029647 Apoptosis-associated speck-like protein containing a CARD Human genes 0.000 description 6
- 102100023275 Dual specificity mitogen-activated protein kinase kinase 3 Human genes 0.000 description 6
- 102100023274 Dual specificity mitogen-activated protein kinase kinase 4 Human genes 0.000 description 6
- 102100023401 Dual specificity mitogen-activated protein kinase kinase 6 Human genes 0.000 description 6
- 102100023332 Dual specificity mitogen-activated protein kinase kinase 7 Human genes 0.000 description 6
- 101001115394 Homo sapiens Dual specificity mitogen-activated protein kinase kinase 3 Proteins 0.000 description 6
- 101001115395 Homo sapiens Dual specificity mitogen-activated protein kinase kinase 4 Proteins 0.000 description 6
- 101000624426 Homo sapiens Dual specificity mitogen-activated protein kinase kinase 6 Proteins 0.000 description 6
- 101000624594 Homo sapiens Dual specificity mitogen-activated protein kinase kinase 7 Proteins 0.000 description 6
- 101000852255 Homo sapiens Interleukin-1 receptor-associated kinase-like 2 Proteins 0.000 description 6
- 101000674728 Homo sapiens TGF-beta-activated kinase 1 and MAP3K7-binding protein 2 Proteins 0.000 description 6
- 101000674732 Homo sapiens TGF-beta-activated kinase 1 and MAP3K7-binding protein 3 Proteins 0.000 description 6
- 102100036433 Interleukin-1 receptor-associated kinase-like 2 Human genes 0.000 description 6
- 102100026888 Mitogen-activated protein kinase kinase kinase 7 Human genes 0.000 description 6
- 102100021227 TGF-beta-activated kinase 1 and MAP3K7-binding protein 2 Human genes 0.000 description 6
- 102100021229 TGF-beta-activated kinase 1 and MAP3K7-binding protein 3 Human genes 0.000 description 6
- 102000004399 TNF receptor-associated factor 3 Human genes 0.000 description 6
- 108090000922 TNF receptor-associated factor 3 Proteins 0.000 description 6
- 230000036755 cellular response Effects 0.000 description 6
- 230000037361 pathway Effects 0.000 description 6
- 230000011664 signaling Effects 0.000 description 6
- 108091008743 testicular receptors 4 Proteins 0.000 description 6
- 102100037435 Antiviral innate immune response receptor RIG-I Human genes 0.000 description 5
- 101710127675 Antiviral innate immune response receptor RIG-I Proteins 0.000 description 5
- 108010034143 Inflammasomes Proteins 0.000 description 5
- 229940079593 drug Drugs 0.000 description 5
- 230000000694 effects Effects 0.000 description 5
- 230000028996 humoral immune response Effects 0.000 description 5
- 230000021633 leukocyte mediated immunity Effects 0.000 description 5
- 230000021597 necroptosis Effects 0.000 description 5
- UVBYMVOUBXYSFV-XUTVFYLZSA-N 1-methylpseudouridine Chemical compound O=C1NC(=O)N(C)C=C1[C@H]1[C@H](O)[C@H](O)[C@@H](CO)O1 UVBYMVOUBXYSFV-XUTVFYLZSA-N 0.000 description 4
- 102100026882 Alpha-synuclein Human genes 0.000 description 4
- 102000008096 B7-H1 Antigen Human genes 0.000 description 4
- 101710090338 Caspase-4 Proteins 0.000 description 4
- 102100025597 Caspase-4 Human genes 0.000 description 4
- 102100039928 Gamma-interferon-inducible protein 16 Human genes 0.000 description 4
- 101000960209 Homo sapiens Gamma-interferon-inducible protein 16 Proteins 0.000 description 4
- 101001018097 Homo sapiens L-selectin Proteins 0.000 description 4
- 101000595548 Homo sapiens TIR domain-containing adapter molecule 1 Proteins 0.000 description 4
- 101710090028 Inositol-3-phosphate synthase 1 Proteins 0.000 description 4
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 4
- 102100033467 L-selectin Human genes 0.000 description 4
- 230000006052 T cell proliferation Effects 0.000 description 4
- 102100036073 TIR domain-containing adapter molecule 1 Human genes 0.000 description 4
- 108091023040 Transcription factor Proteins 0.000 description 4
- 102000040945 Transcription factor Human genes 0.000 description 4
- 102100040310 Z-DNA-binding protein 1 Human genes 0.000 description 4
- 101710181770 Z-DNA-binding protein 1 Proteins 0.000 description 4
- 150000001413 amino acids Chemical class 0.000 description 4
- 239000012636 effector Substances 0.000 description 4
- 102000004169 proteins and genes Human genes 0.000 description 4
- 108090000623 proteins and genes Proteins 0.000 description 4
- UVBYMVOUBXYSFV-UHFFFAOYSA-N 1-methylpseudouridine Natural products O=C1NC(=O)N(C)C=C1C1C(O)C(O)C(CO)O1 UVBYMVOUBXYSFV-UHFFFAOYSA-N 0.000 description 3
- GJTBSTBJLVYKAU-XVFCMESISA-N 2-thiouridine Chemical compound O[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1N1C(=S)NC(=O)C=C1 GJTBSTBJLVYKAU-XVFCMESISA-N 0.000 description 3
- QBWKPGNFQQJGFY-QLFBSQMISA-N 3-[(1r)-1-[(2r,6s)-2,6-dimethylmorpholin-4-yl]ethyl]-n-[6-methyl-3-(1h-pyrazol-4-yl)imidazo[1,2-a]pyrazin-8-yl]-1,2-thiazol-5-amine Chemical compound N1([C@H](C)C2=NSC(NC=3C4=NC=C(N4C=C(C)N=3)C3=CNN=C3)=C2)C[C@H](C)O[C@H](C)C1 QBWKPGNFQQJGFY-QLFBSQMISA-N 0.000 description 3
- 102100038916 Caspase-5 Human genes 0.000 description 3
- 101710090333 Caspase-5 Proteins 0.000 description 3
- 102100026693 FAS-associated death domain protein Human genes 0.000 description 3
- 101000728679 Homo sapiens Apoptosis-associated speck-like protein containing a CARD Proteins 0.000 description 3
- 101000911074 Homo sapiens FAS-associated death domain protein Proteins 0.000 description 3
- 101001089266 Homo sapiens Receptor-interacting serine/threonine-protein kinase 3 Proteins 0.000 description 3
- 101000933115 Mus musculus Caspase-4 Proteins 0.000 description 3
- 229930185560 Pseudouridine Natural products 0.000 description 3
- PTJWIQPHWPFNBW-UHFFFAOYSA-N Pseudouridine C Natural products OC1C(O)C(CO)OC1C1=CNC(=O)NC1=O PTJWIQPHWPFNBW-UHFFFAOYSA-N 0.000 description 3
- 108010059278 Pyrin Proteins 0.000 description 3
- 102000005583 Pyrin Human genes 0.000 description 3
- 108010001946 Pyrin Domain-Containing 3 Protein NLR Family Proteins 0.000 description 3
- 102000000874 Pyrin Domain-Containing 3 Protein NLR Family Human genes 0.000 description 3
- 102100033729 Receptor-interacting serine/threonine-protein kinase 3 Human genes 0.000 description 3
- 102000035181 adaptor proteins Human genes 0.000 description 3
- 108091005764 adaptor proteins Proteins 0.000 description 3
- WGDUUQDYDIIBKT-UHFFFAOYSA-N beta-Pseudouridine Natural products OC1OC(CN2C=CC(=O)NC2=O)C(O)C1O WGDUUQDYDIIBKT-UHFFFAOYSA-N 0.000 description 3
- 229940125846 compound 25 Drugs 0.000 description 3
- 210000004443 dendritic cell Anatomy 0.000 description 3
- 230000018109 developmental process Effects 0.000 description 3
- 230000006870 function Effects 0.000 description 3
- 230000028709 inflammatory response Effects 0.000 description 3
- 230000003834 intracellular effect Effects 0.000 description 3
- 230000031146 intracellular signal transduction Effects 0.000 description 3
- PTJWIQPHWPFNBW-GBNDHIKLSA-N pseudouridine Chemical compound O[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1C1=CNC(=O)NC1=O PTJWIQPHWPFNBW-GBNDHIKLSA-N 0.000 description 3
- 230000007115 recruitment Effects 0.000 description 3
- MZOFCQQQCNRIBI-VMXHOPILSA-N (3s)-4-[[(2s)-1-[[(2s)-1-[[(1s)-1-carboxy-2-hydroxyethyl]amino]-4-methyl-1-oxopentan-2-yl]amino]-5-(diaminomethylideneamino)-1-oxopentan-2-yl]amino]-3-[[2-[[(2s)-2,6-diaminohexanoyl]amino]acetyl]amino]-4-oxobutanoic acid Chemical compound OC[C@@H](C(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CC(O)=O)NC(=O)CNC(=O)[C@@H](N)CCCCN MZOFCQQQCNRIBI-VMXHOPILSA-N 0.000 description 2
- SXUXMRMBWZCMEN-UHFFFAOYSA-N 2'-O-methyl uridine Natural products COC1C(O)C(CO)OC1N1C(=O)NC(=O)C=C1 SXUXMRMBWZCMEN-UHFFFAOYSA-N 0.000 description 2
- SXUXMRMBWZCMEN-ZOQUXTDFSA-N 2'-O-methyluridine Chemical compound CO[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1N1C(=O)NC(=O)C=C1 SXUXMRMBWZCMEN-ZOQUXTDFSA-N 0.000 description 2
- LRFJOIPOPUJUMI-KWXKLSQISA-N 2-[2,2-bis[(9z,12z)-octadeca-9,12-dienyl]-1,3-dioxolan-4-yl]-n,n-dimethylethanamine Chemical compound CCCCC\C=C/C\C=C/CCCCCCCCC1(CCCCCCCC\C=C/C\C=C/CCCCC)OCC(CCN(C)C)O1 LRFJOIPOPUJUMI-KWXKLSQISA-N 0.000 description 2
- 108091028732 Concatemer Proteins 0.000 description 2
- 102100037388 Gasdermin-D Human genes 0.000 description 2
- 101001026262 Homo sapiens Gasdermin-D Proteins 0.000 description 2
- 102100037850 Interferon gamma Human genes 0.000 description 2
- 108010074328 Interferon-gamma Proteins 0.000 description 2
- 102000043129 MHC class I family Human genes 0.000 description 2
- 108091054437 MHC class I family Proteins 0.000 description 2
- 102000043131 MHC class II family Human genes 0.000 description 2
- 108091054438 MHC class II family Proteins 0.000 description 2
- VQAYFKKCNSOZKM-IOSLPCCCSA-N N(6)-methyladenosine Chemical compound C1=NC=2C(NC)=NC=NC=2N1[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O VQAYFKKCNSOZKM-IOSLPCCCSA-N 0.000 description 2
- 108060008682 Tumor Necrosis Factor Proteins 0.000 description 2
- 102100040247 Tumor necrosis factor Human genes 0.000 description 2
- 230000008350 antigen-specific antibody response Effects 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- 210000002443 helper t lymphocyte Anatomy 0.000 description 2
- 102000053956 human IRF7 Human genes 0.000 description 2
- 230000016784 immunoglobulin production Effects 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- 244000052769 pathogen Species 0.000 description 2
- 230000001717 pathogenic effect Effects 0.000 description 2
- 230000019491 signal transduction Effects 0.000 description 2
- 230000010472 type I IFN response Effects 0.000 description 2
- ODDDVFDZBGTKDX-VPCXQMTMSA-N 1-[(2r,3r,4s,5r)-3,4-dihydroxy-5-(hydroxymethyl)-2-methyloxolan-2-yl]pyrimidine-2,4-dione Chemical compound C1=CC(=O)NC(=O)N1[C@]1(C)O[C@H](CO)[C@@H](O)[C@H]1O ODDDVFDZBGTKDX-VPCXQMTMSA-N 0.000 description 1
- KYEKLQMDNZPEFU-KVTDHHQDSA-N 1-[(2r,3r,4s,5r)-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]-1,3,5-triazine-2,4-dione Chemical compound O[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1N1C(=O)NC(=O)N=C1 KYEKLQMDNZPEFU-KVTDHHQDSA-N 0.000 description 1
- MUSPKJVFRAYWAR-XVFCMESISA-N 1-[(2r,3r,4s,5r)-3,4-dihydroxy-5-(hydroxymethyl)thiolan-2-yl]pyrimidine-2,4-dione Chemical compound O[C@@H]1[C@H](O)[C@@H](CO)S[C@H]1N1C(=O)NC(=O)C=C1 MUSPKJVFRAYWAR-XVFCMESISA-N 0.000 description 1
- BVLGKOVALHRKNM-XUTVFYLZSA-N 2-Thio-1-methylpseudouridine Chemical compound CN1C=C(C(=O)NC1=S)[C@H]2[C@@H]([C@@H]([C@H](O2)CO)O)O BVLGKOVALHRKNM-XUTVFYLZSA-N 0.000 description 1
- CWXIOHYALLRNSZ-JWMKEVCDSA-N 2-Thiodihydropseudouridine Chemical compound C1C(C(=O)NC(=S)N1)[C@H]2[C@@H]([C@@H]([C@H](O2)CO)O)O CWXIOHYALLRNSZ-JWMKEVCDSA-N 0.000 description 1
- VRVXMIJPUBNPGH-XVFCMESISA-N 2-thio-dihydrouridine Chemical compound OC[C@H]1O[C@H]([C@H](O)[C@@H]1O)N1CCC(=O)NC1=S VRVXMIJPUBNPGH-XVFCMESISA-N 0.000 description 1
- FGFVODMBKZRMMW-XUTVFYLZSA-N 4-Methoxy-2-thiopseudouridine Chemical compound COC1=C(C=NC(=S)N1)[C@H]2[C@@H]([C@@H]([C@H](O2)CO)O)O FGFVODMBKZRMMW-XUTVFYLZSA-N 0.000 description 1
- HOCJTJWYMOSXMU-XUTVFYLZSA-N 4-Methoxypseudouridine Chemical compound COC1=C(C=NC(=O)N1)[C@H]2[C@@H]([C@@H]([C@H](O2)CO)O)O HOCJTJWYMOSXMU-XUTVFYLZSA-N 0.000 description 1
- VTGBLFNEDHVUQA-XUTVFYLZSA-N 4-Thio-1-methyl-pseudouridine Chemical compound S=C1NC(=O)N(C)C=C1[C@H]1[C@H](O)[C@H](O)[C@@H](CO)O1 VTGBLFNEDHVUQA-XUTVFYLZSA-N 0.000 description 1
- DDHOXEOVAJVODV-GBNDHIKLSA-N 5-[(2s,3r,4s,5r)-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]-2-sulfanylidene-1h-pyrimidin-4-one Chemical compound O[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1C1=CNC(=S)NC1=O DDHOXEOVAJVODV-GBNDHIKLSA-N 0.000 description 1
- BNAWMJKJLNJZFU-GBNDHIKLSA-N 5-[(2s,3r,4s,5r)-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]-4-sulfanylidene-1h-pyrimidin-2-one Chemical compound O[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1C1=CNC(=O)NC1=S BNAWMJKJLNJZFU-GBNDHIKLSA-N 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- YKWUPFSEFXSGRT-JWMKEVCDSA-N Dihydropseudouridine Chemical compound O[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1C1C(=O)NC(=O)NC1 YKWUPFSEFXSGRT-JWMKEVCDSA-N 0.000 description 1
- 102100028972 HLA class I histocompatibility antigen, A alpha chain Human genes 0.000 description 1
- 102100028976 HLA class I histocompatibility antigen, B alpha chain Human genes 0.000 description 1
- 108010075704 HLA-A Antigens Proteins 0.000 description 1
- 108010058607 HLA-B Antigens Proteins 0.000 description 1
- QCNWZROVPSVEJA-UHFFFAOYSA-N Heptadecanedioic acid Chemical compound OC(=O)CCCCCCCCCCCCCCCC(O)=O QCNWZROVPSVEJA-UHFFFAOYSA-N 0.000 description 1
- 101001100327 Homo sapiens RNA-binding protein 45 Proteins 0.000 description 1
- 102000001702 Intracellular Signaling Peptides and Proteins Human genes 0.000 description 1
- 108010068964 Intracellular Signaling Peptides and Proteins Proteins 0.000 description 1
- 102100038823 RNA-binding protein 45 Human genes 0.000 description 1
- 229930182558 Sterol Natural products 0.000 description 1
- 241000700605 Viruses Species 0.000 description 1
- NRLNQCOGCKAESA-KWXKLSQISA-N [(6z,9z,28z,31z)-heptatriaconta-6,9,28,31-tetraen-19-yl] 4-(dimethylamino)butanoate Chemical compound CCCCC\C=C/C\C=C/CCCCCCCCC(OC(=O)CCCN(C)C)CCCCCCCC\C=C/C\C=C/CCCCC NRLNQCOGCKAESA-KWXKLSQISA-N 0.000 description 1
- 238000003776 cleavage reaction Methods 0.000 description 1
- 238000012217 deletion Methods 0.000 description 1
- 230000037430 deletion Effects 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- 230000002434 immunopotentiative effect Effects 0.000 description 1
- 238000010253 intravenous injection Methods 0.000 description 1
- 239000002773 nucleotide Substances 0.000 description 1
- 244000045947 parasite Species 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 1
- 230000007017 scission Effects 0.000 description 1
- 150000003432 sterols Chemical class 0.000 description 1
- 235000003702 sterols Nutrition 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2022143786A JP2022184924A (ja) | 2016-10-26 | 2022-09-09 | 免疫応答を増強するためのメッセンジャーリボ核酸及びその使用方法 |
Applications Claiming Priority (9)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662412933P | 2016-10-26 | 2016-10-26 | |
| US62/412,933 | 2016-10-26 | ||
| US201762467034P | 2017-03-03 | 2017-03-03 | |
| US62/467,034 | 2017-03-03 | ||
| US201762490522P | 2017-04-26 | 2017-04-26 | |
| US62/490,522 | 2017-04-26 | ||
| US201762558206P | 2017-09-13 | 2017-09-13 | |
| US62/558,206 | 2017-09-13 | ||
| PCT/US2017/058585 WO2018081459A1 (en) | 2016-10-26 | 2017-10-26 | Messenger ribonucleic acids for enhancing immune responses and methods of use thereof |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022143786A Division JP2022184924A (ja) | 2016-10-26 | 2022-09-09 | 免疫応答を増強するためのメッセンジャーリボ核酸及びその使用方法 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2019532657A JP2019532657A (ja) | 2019-11-14 |
| JP2019532657A5 true JP2019532657A5 (enExample) | 2020-12-03 |
Family
ID=60570181
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019522512A Pending JP2019532657A (ja) | 2016-10-26 | 2017-10-26 | 免疫応答を増強するためのメッセンジャーリボ核酸及びその使用方法 |
| JP2022143786A Pending JP2022184924A (ja) | 2016-10-26 | 2022-09-09 | 免疫応答を増強するためのメッセンジャーリボ核酸及びその使用方法 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022143786A Pending JP2022184924A (ja) | 2016-10-26 | 2022-09-09 | 免疫応答を増強するためのメッセンジャーリボ核酸及びその使用方法 |
Country Status (13)
| Country | Link |
|---|---|
| US (3) | US20180311343A1 (enExample) |
| EP (1) | EP3532070A1 (enExample) |
| JP (2) | JP2019532657A (enExample) |
| KR (1) | KR20190086681A (enExample) |
| CN (1) | CN110402145A (enExample) |
| AU (1) | AU2017347837A1 (enExample) |
| BR (1) | BR112019008369A2 (enExample) |
| CA (1) | CA3042015A1 (enExample) |
| IL (1) | IL266222A (enExample) |
| MX (1) | MX2019004810A (enExample) |
| RU (1) | RU2765874C2 (enExample) |
| SG (1) | SG11201903674YA (enExample) |
| WO (1) | WO2018081459A1 (enExample) |
Families Citing this family (122)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US9464124B2 (en) | 2011-09-12 | 2016-10-11 | Moderna Therapeutics, Inc. | Engineered nucleic acids and methods of use thereof |
| PT3134131T (pt) | 2014-04-23 | 2022-03-24 | Modernatx Inc | Vacinas de ácidos nucleicos |
| EP4218805A1 (en) | 2015-07-21 | 2023-08-02 | ModernaTX, Inc. | Infectious disease vaccines |
| US11364292B2 (en) | 2015-07-21 | 2022-06-21 | Modernatx, Inc. | CHIKV RNA vaccines |
| EP3328394A4 (en) | 2015-07-30 | 2019-03-13 | ModernaTX, Inc. | CONCATEMEE peptide epitope RNAs |
| WO2017031232A1 (en) | 2015-08-17 | 2017-02-23 | Modernatx, Inc. | Methods for preparing particles and related compositions |
| CA3002922A1 (en) | 2015-10-22 | 2017-04-27 | Modernatx, Inc. | Human cytomegalovirus vaccine |
| EP3364950A4 (en) | 2015-10-22 | 2019-10-23 | ModernaTX, Inc. | VACCINES AGAINST TROPICAL DISEASES |
| MA45209A (fr) | 2015-10-22 | 2019-04-17 | Modernatx Inc | Vaccins contre les maladies sexuellement transmissibles |
| SG11201803360UA (en) | 2015-10-22 | 2018-05-30 | Modernatx Inc | Nucleic acid vaccines for varicella zoster virus (vzv) |
| EP4349404A3 (en) | 2015-10-22 | 2024-06-19 | ModernaTX, Inc. | Respiratory virus vaccines |
| EP3386484B1 (en) | 2015-12-10 | 2022-03-30 | ModernaTX, Inc. | Compositions and methods for delivery of therapeutic agents |
| US10465190B1 (en) | 2015-12-23 | 2019-11-05 | Modernatx, Inc. | In vitro transcription methods and constructs |
| US10188749B2 (en) | 2016-04-14 | 2019-01-29 | Fred Hutchinson Cancer Research Center | Compositions and methods to program therapeutic cells using targeted nucleic acid nanocarriers |
| IL263079B2 (en) | 2016-05-18 | 2024-05-01 | Modernatx Inc | Polynucleotides encoding relaxin |
| MA45052A (fr) | 2016-05-18 | 2019-03-27 | Modernatx Inc | Polynucléotides codant pour jagged1 pour le traitement du syndrome d'alagille |
| SG11201901941YA (en) | 2016-09-14 | 2019-04-29 | Modernatx Inc | High purity rna compositions and methods for preparation thereof |
| EP3528821A4 (en) | 2016-10-21 | 2020-07-01 | ModernaTX, Inc. | HUMAN CYTOMEGALOVIRUS VACCINE |
| WO2018089851A2 (en) | 2016-11-11 | 2018-05-17 | Modernatx, Inc. | Influenza vaccine |
| WO2018107088A2 (en) | 2016-12-08 | 2018-06-14 | Modernatx, Inc. | Respiratory virus nucleic acid vaccines |
| US11384352B2 (en) | 2016-12-13 | 2022-07-12 | Modernatx, Inc. | RNA affinity purification |
| US11572389B2 (en) * | 2017-01-27 | 2023-02-07 | The Henry M. Jackson Foundation For The Advancement Of Military Medicine, Inc. | Vaccine compositions of herpesvirus envelope protein combinations to induce immune response |
| AU2018214556A1 (en) * | 2017-02-01 | 2019-08-15 | Modernatx, Inc. | Immunomodulatory therapeutic mRNA compositions encoding activating oncogene mutation peptides |
| JP7731656B2 (ja) * | 2017-02-01 | 2025-09-01 | モデルナティエックス インコーポレイテッド | Ｒｎａ癌ワクチン |
| EP3582790A4 (en) | 2017-02-16 | 2020-11-25 | ModernaTX, Inc. | VERY POWERFUL IMMUNOGENIC COMPOSITIONS |
| US11752206B2 (en) | 2017-03-15 | 2023-09-12 | Modernatx, Inc. | Herpes simplex virus vaccine |
| EP3595713A4 (en) | 2017-03-15 | 2021-01-13 | ModernaTX, Inc. | Respiratory syncytial virus vaccine |
| US11576961B2 (en) | 2017-03-15 | 2023-02-14 | Modernatx, Inc. | Broad spectrum influenza virus vaccine |
| WO2018170270A1 (en) | 2017-03-15 | 2018-09-20 | Modernatx, Inc. | Varicella zoster virus (vzv) vaccine |
| EP3595676A4 (en) | 2017-03-17 | 2021-05-05 | Modernatx, Inc. | RNA VACCINES AGAINST ZOONOSES |
| US11905525B2 (en) | 2017-04-05 | 2024-02-20 | Modernatx, Inc. | Reduction of elimination of immune responses to non-intravenous, e.g., subcutaneously administered therapeutic proteins |
| ES2952779T3 (es) | 2017-05-18 | 2023-11-06 | Modernatx Inc | ARN mensajero modificado que comprende elementos de ARN funcionales |
| EP3638215A4 (en) | 2017-06-15 | 2021-03-24 | Modernatx, Inc. | RNA FORMULATIONS |
| CA3069523A1 (en) | 2017-07-11 | 2019-01-17 | Actym Therapeutics, Inc. | Engineered immunostimulatory bacterial strains and uses thereof |
| WO2019035901A1 (en) * | 2017-08-15 | 2019-02-21 | University Of Miami | COMPOSITIONS AND METHODS FOR STING PROTEIN MODULATION |
| WO2019036683A1 (en) | 2017-08-18 | 2019-02-21 | Modernatx, Inc. | ANALYTICAL METHODS BY HPLC |
| WO2019036685A1 (en) | 2017-08-18 | 2019-02-21 | Modernatx, Inc. | METHODS FOR HPLC ANALYSIS |
| CN111212905A (zh) | 2017-08-18 | 2020-05-29 | 摩登纳特斯有限公司 | Rna聚合酶变体 |
| CA3073211A1 (en) | 2017-08-31 | 2019-03-07 | Modernatx, Inc. | Methods of making lipid nanoparticles |
| GB201714430D0 (en) | 2017-09-07 | 2017-10-25 | Micol Romain | Compositions and processes for targeted delivery and expression and modulation of therapeutic components in tissue |
| EP3681514A4 (en) | 2017-09-14 | 2021-07-14 | ModernaTX, Inc. | RNA VACZINE AGAINST ZIKA VIRUS |
| BR112020012538A2 (pt) | 2017-12-21 | 2020-11-24 | Baseclick Gmbh | mrna click-modificado |
| KR102822683B1 (ko) * | 2018-01-18 | 2025-06-20 | 프레드 허친슨 캔서 센터 | 세포 활성화 상태를 조절함으로써 생체내 면역 세포의 염증 상태의 변경 |
| US11911453B2 (en) | 2018-01-29 | 2024-02-27 | Modernatx, Inc. | RSV RNA vaccines |
| JP2021512090A (ja) * | 2018-01-30 | 2021-05-13 | モデルナティーエックス， インコーポレイテッド | 免疫細胞に薬剤を送達するための組成物及び方法 |
| US20210017541A1 (en) * | 2018-03-26 | 2021-01-21 | University Of Miami | Recombinant viral vector and uses thereof |
| EP3773745A1 (en) * | 2018-04-11 | 2021-02-17 | ModernaTX, Inc. | Messenger rna comprising functional rna elements |
| US20200016274A1 (en) * | 2018-05-30 | 2020-01-16 | Translate Bio, Inc. | Messenger rna vaccines and uses thereof |
| US11981909B2 (en) | 2018-06-06 | 2024-05-14 | Massachusetts Institute Of Technology | Circular RNA for translation in eukaryotic cells |
| WO2020014543A2 (en) | 2018-07-11 | 2020-01-16 | Actym Therapeutics, Inc. | Engineered immunostimulatory bacterial strains and uses thereof |
| WO2020028743A1 (en) * | 2018-08-03 | 2020-02-06 | Board Of Trustees Of Michigan State University | Compositions of sting variants, combinations thereof, and methods for inducing and enhancing an immune response against infections, diseases, and disorders |
| US20220002730A1 (en) * | 2018-08-24 | 2022-01-06 | City Of Hope | Oligonucleotide inhibitors of nuclear factor kappa-light-chain-enhancer of activated b cells and the uses thereof |
| WO2020047161A2 (en) | 2018-08-28 | 2020-03-05 | Actym Therapeutics, Inc. | Engineered immunostimulatory bacterial strains and uses thereof |
| US12151029B2 (en) | 2018-09-19 | 2024-11-26 | Modernatx, Inc. | PEG lipids and uses thereof |
| EP4509118A3 (en) | 2018-09-19 | 2025-05-14 | ModernaTX, Inc. | High-purity peg lipids and uses thereof |
| CN113271926A (zh) | 2018-09-20 | 2021-08-17 | 摩登纳特斯有限公司 | 脂质纳米颗粒的制备及其施用方法 |
| EP3898942A4 (en) * | 2018-12-21 | 2022-10-19 | Tiba Biotech LLC | NANOPARTICLE COMPOSITIONS FOR EFFICIENT NUCLEIC ACID DELIVERY AND METHODS OF MAKING AND USE THEREOF |
| CN109762895A (zh) * | 2019-01-07 | 2019-05-17 | 中国医学科学院北京协和医院 | miR-146a在制备诊断激素性股骨头坏死产品中的应用 |
| EP3683229A1 (en) * | 2019-01-21 | 2020-07-22 | Charité - Universitätsmedizin Berlin | Specific t cell receptors against epitopes of mutant myd88l265p protein for adoptive t cell therapy |
| US11351242B1 (en) | 2019-02-12 | 2022-06-07 | Modernatx, Inc. | HMPV/hPIV3 mRNA vaccine composition |
| US11851694B1 (en) | 2019-02-20 | 2023-12-26 | Modernatx, Inc. | High fidelity in vitro transcription |
| MA55037A (fr) | 2019-02-20 | 2021-12-29 | Modernatx Inc | Variants d'arn polymérase pour le coiffage co-transcriptionnel |
| BR112021016728A2 (pt) | 2019-02-27 | 2022-01-11 | Actym Therapeutics Inc | Bactérias imunostimulatórias projetadas para colonizar tumores, residentes em tumores células imunológicas e o microambiente tumoral |
| US12024709B2 (en) | 2019-02-27 | 2024-07-02 | Actym Therapeutics, Inc. | Immunostimulatory bacteria engineered to colonize tumors, tumor-resident immune cells, and the tumor microenvironment |
| EP3938507A4 (en) | 2019-03-11 | 2023-02-22 | ModernaTX, Inc. | PROCEDURE FOR IN VITRO FED BATCH TRANSCRIPTION |
| MA55321A (fr) | 2019-03-15 | 2022-01-19 | Modernatx Inc | Vaccins à base d'arn contre le vih |
| WO2020204714A1 (en) | 2019-04-02 | 2020-10-08 | Immunetune B.V. | Immune-stimulatory compositions and use thereof |
| CN115867291A (zh) | 2019-05-22 | 2023-03-28 | 麻省理工学院 | 环状rna组合物和方法 |
| AU2020299636A1 (en) * | 2019-07-03 | 2022-02-24 | The Walter And Eliza Hall Institute Of Medical Research | Compositions and methods of use |
| WO2021062037A1 (en) * | 2019-09-24 | 2021-04-01 | Auburn University | Phage-peptide constructs for stimulation of an anti-cancer immune response against cd47 |
| EP4041400B1 (en) * | 2019-10-09 | 2025-02-26 | Translate Bio, Inc. | Messenger rnas encoding sting and il-12 and use in the treatment of cancer |
| WO2021081296A1 (en) * | 2019-10-24 | 2021-04-29 | Joshua Labaer | Novel antibodies for detecting epstein barr virus-positive gastric cancer |
| CA3177479A1 (en) | 2019-11-12 | 2021-05-20 | Actym Therapeutics, Inc. | Immunostimulatory bacteria delivery platforms and their use for delivery of therapeutic products |
| CN114641315A (zh) * | 2019-11-14 | 2022-06-17 | 博阿济吉大学 | 癌症免疫疗法中的asc斑点 |
| JPWO2021095838A1 (enExample) * | 2019-11-15 | 2021-05-20 | ||
| WO2021108025A1 (en) * | 2019-11-26 | 2021-06-03 | Massachusetts Institute Of Technology | Cell-based cancer vaccines and cancer therapies |
| AU2020397956A1 (en) | 2019-12-04 | 2022-07-07 | Orna Therapeutics, Inc. | Circular RNA compositions and methods |
| ES3041492T3 (en) | 2019-12-18 | 2025-11-12 | Stinginn Llc | Substituted 1,2, 4-triazoles and methods of use |
| CN110974954B (zh) * | 2019-12-24 | 2021-03-16 | 珠海丽凡达生物技术有限公司 | 一种用于增强核酸疫苗免疫效果的脂质纳米颗粒及其制备方法 |
| WO2021168266A1 (en) * | 2020-02-21 | 2021-08-26 | Temple University - Of The Commonwealth System Of Higher Education | Eradication of merkel cell polyomavirus |
| MX2022010084A (es) * | 2020-02-21 | 2022-12-07 | Combined Therapeutics Inc | Composiciones y métodos para la expresión y modulación protectoras de órganos de ácidos ribonucleicos codificantes. |
| WO2021197589A1 (en) * | 2020-03-31 | 2021-10-07 | BioNTech SE | Treatment involving non-immunogenic rna for antigen vaccination |
| EP3901261A1 (en) | 2020-04-22 | 2021-10-27 | BioNTech RNA Pharmaceuticals GmbH | Coronavirus vaccine |
| CN115956003A (zh) * | 2020-04-22 | 2023-04-11 | 胡桃钳医疗公司 | mRNA治疗纳米颗粒 |
| US11897888B1 (en) | 2020-04-30 | 2024-02-13 | Stinginn Llc | Small molecular inhibitors of sting signaling compositions and methods of use |
| EP4178611A1 (en) * | 2020-07-07 | 2023-05-17 | BioNTech SE | Therapeutic rna for hpv-positive cancer |
| CN116209771A (zh) * | 2020-07-31 | 2023-06-02 | 联合治疗公司 | 用于改善疫苗接种的组合物和方法 |
| CA3187258A1 (en) * | 2020-08-06 | 2022-02-10 | Karin Jooss | Multiepitope vaccine cassettes |
| JP2023539454A (ja) | 2020-08-12 | 2023-09-14 | アクティム・セラピューティクス・インコーポレイテッド | 免疫刺激細菌ベースのワクチン、治療薬およびｒｎａデリバリープラットフォーム |
| US11406703B2 (en) | 2020-08-25 | 2022-08-09 | Modernatx, Inc. | Human cytomegalovirus vaccine |
| EP4228679A1 (en) * | 2020-10-14 | 2023-08-23 | Rnaimmune, Inc. | Pan-ras mrna cancer vaccines |
| GB202017119D0 (en) * | 2020-10-28 | 2020-12-09 | Oxford Vacmedix Uk Ltd | Polypeptides for cancer treatment |
| US11058751B1 (en) | 2020-11-20 | 2021-07-13 | Think Therapeutics, Inc. | Compositions for optimized RAS peptide vaccines |
| AU2021381384A1 (en) * | 2020-11-20 | 2023-06-22 | Think Therapeutics, Inc. | Compositions and methods for optimized peptide vaccines |
| CN116710115A (zh) | 2020-11-20 | 2023-09-05 | 思维疗法股份有限公司 | 用于优化的肽疫苗的组合物和方法 |
| GB202020063D0 (en) * | 2020-12-17 | 2021-02-03 | Imperial College Innovations Ltd | RNA construct |
| US20240067684A1 (en) * | 2020-12-23 | 2024-02-29 | Kernal Biologics, Inc. | Constitutively active payloads |
| US12329811B2 (en) | 2021-01-11 | 2025-06-17 | Modernatx, Inc. | Seasonal RNA influenza virus vaccines |
| US20240082378A1 (en) * | 2021-01-15 | 2024-03-14 | University Of Rochester | Staphylococcus aureus Antigen-Based Nucleic Acid Vaccines |
| US11524023B2 (en) | 2021-02-19 | 2022-12-13 | Modernatx, Inc. | Lipid nanoparticle compositions and methods of formulating the same |
| WO2022212784A1 (en) * | 2021-03-31 | 2022-10-06 | Flagship Pioneering Innovations V, Inc. | Thanotransmission polypeptides and their use in treating cancer |
| CN113509542A (zh) * | 2021-04-20 | 2021-10-19 | 嘉晨西海(杭州)生物技术有限公司 | 一种基于mRNA的表达白介素12针对肿瘤的药物及其制备方法 |
| US20220363937A1 (en) | 2021-05-14 | 2022-11-17 | Armstrong World Industries, Inc. | Stabilization of antimicrobial coatings |
| EP4342993A4 (en) * | 2021-05-19 | 2025-05-28 | Daiichi Sankyo Company, Limited | Hpv infectious disease vaccine |
| WO2022256637A2 (en) * | 2021-06-03 | 2022-12-08 | David Weiner | Synthetic dna vaccine immunogenic improvements |
| US20240358821A1 (en) * | 2021-07-06 | 2024-10-31 | The Trustees Of The University Of Pennsylvania | P7 Containing Nucleoside-modified mRNA-lipid Nanoparticle Lineage Vaccine for Hepatitis C Virus |
| CN113616793B (zh) * | 2021-08-20 | 2023-07-04 | 南方海洋科学与工程广东省实验室(湛江) | Traf6抑制剂在作为和/或制备铁死亡诱导剂中的应用 |
| WO2023076131A2 (en) * | 2021-10-25 | 2023-05-04 | The Regents Of The University Of California | Kaposi sarcoma associated herpesvirus gene function |
| EP4429682A2 (en) | 2021-11-09 | 2024-09-18 | Actym Therapeutics, Inc. | Immunostimulatory bacteria for converting macrophages into a phenotype amenable to treatment, and companion diagnostic for identifying subjects for treatment |
| CN113952359A (zh) * | 2021-11-19 | 2022-01-21 | 大连理工大学盘锦产业技术研究院 | 顺铂与Tri-1的联合抗肺癌药物组合物及其应用 |
| US12186387B2 (en) | 2021-11-29 | 2025-01-07 | BioNTech SE | Coronavirus vaccine |
| WO2023125974A1 (zh) * | 2021-12-31 | 2023-07-06 | 广州国家实验室 | mRNA疫苗 |
| CN118829624A (zh) * | 2022-01-17 | 2024-10-22 | 赛诺菲 | 脂质化合物及其用途 |
| US20250213664A1 (en) * | 2022-02-18 | 2025-07-03 | Modernatx, Inc. | Mrnas encoding checkpoint cancer vaccines and uses thereof |
| US12297285B2 (en) | 2022-06-24 | 2025-05-13 | Orna Therapeutics, Inc. | Circular RNA encoding chimeric antigen receptors targeting BCMA |
| US11878055B1 (en) | 2022-06-26 | 2024-01-23 | BioNTech SE | Coronavirus vaccine |
| CN115089588A (zh) * | 2022-08-22 | 2022-09-23 | 云南大学 | 达沙布韦作为e3连接酶新型配体构建protac的应用 |
| WO2025087266A1 (en) * | 2023-10-23 | 2025-05-01 | Abogen Biosciences (Shanghai) Co., Ltd. | Immunomodulatory mrna cassettes, and uses thereof |
| WO2025087250A1 (en) * | 2023-10-23 | 2025-05-01 | Abogen Biosciences (Shanghai) Co., Ltd. | Therapeutic mrna cancer vaccine targeting hpv-associated cancers |
| US20250177432A1 (en) * | 2023-12-04 | 2025-06-05 | Wuhan Houxian Biopharmaceutical Co. Ltd. | Rna molecules and compositions for cancer immunotherapy |
| WO2025153053A1 (en) * | 2024-01-17 | 2025-07-24 | Abogen Biosciences (Shanghai) Co., Ltd. | Composition and methods for inducing antigen specific immunity against kras mutant cells |
| CN118839285B (zh) * | 2024-08-05 | 2025-03-18 | 洛阳莱普生信息科技有限公司 | 基于智能耳标的畜牧生物资产监管方法及系统 |
Family Cites Families (65)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5013556A (en) | 1989-10-20 | 1991-05-07 | Liposome Technology, Inc. | Liposomes with enhanced circulation time |
| AU3559695A (en) | 1994-09-30 | 1996-04-26 | Inex Pharmaceuticals Corp. | Glycosylated protein-liposome conjugates and methods for their preparation |
| EP2428569B1 (en) | 2001-09-28 | 2018-05-23 | Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. | Microrna molecules |
| US20050222064A1 (en) | 2002-02-20 | 2005-10-06 | Sirna Therapeutics, Inc. | Polycationic compositions for cellular delivery of polynucleotides |
| CA2533701A1 (en) | 2003-07-31 | 2005-02-17 | Isis Pharmaceuticals, Inc. | Oligomeric compounds and compositions for use in modulation of small non-coding rnas |
| DE102004035227A1 (de) * | 2004-07-21 | 2006-02-16 | Curevac Gmbh | mRNA-Gemisch zur Vakzinierung gegen Tumorerkrankungen |
| US7404969B2 (en) | 2005-02-14 | 2008-07-29 | Sirna Therapeutics, Inc. | Lipid nanoparticle based compositions and methods for the delivery of biologically active molecules |
| ES2531052T3 (es) | 2006-01-05 | 2015-03-10 | Univ Ohio State Res Found | Métodos y composiciones basados en microARN para el diagnóstico de cánceres de mama |
| CN101384273B (zh) | 2006-01-05 | 2013-07-10 | 俄亥俄州立大学研究基金会 | 胰腺内分泌和腺泡肿瘤中的微小rna表达异常 |
| CA2638844C (en) | 2006-03-02 | 2016-05-03 | Thomas D. Schmittgen | Microrna expression profile associated with pancreatic cancer |
| WO2008036765A2 (en) | 2006-09-19 | 2008-03-27 | Asuragen, Inc. | Micrornas differentially expressed in pancreatic diseases and uses thereof |
| WO2008054828A2 (en) | 2006-11-01 | 2008-05-08 | The Ohio State University Research Foundation | Microrna expression signature for predicting survival and metastases in hepatocellular carcinoma |
| CN101627121A (zh) | 2006-12-08 | 2010-01-13 | 奥斯瑞根公司 | 作为治疗干预的靶标的miRNA调控基因和路径 |
| US8415096B2 (en) | 2007-05-23 | 2013-04-09 | University Of South Florida | Micro-RNAs modulating immunity and inflammation |
| WO2008154098A2 (en) | 2007-06-07 | 2008-12-18 | Wisconsin Alumni Research Foundation | Reagents and methods for mirna expression analysis and identification of cancer biomarkers |
| HUE029164T2 (hu) * | 2007-09-14 | 2017-02-28 | Univ Brussel Vrije | Humán antigén-prezentáló sejtek T-sejteket stimuláló képességének fokozása és azok alkalmazása vakcinázásra |
| CA2707157A1 (en) | 2007-11-30 | 2009-06-04 | The Ohio State University Research Foundation | Microrna expression profiling and targeting in peripheral blood in lung cancer |
| WO2009100430A2 (en) | 2008-02-08 | 2009-08-13 | Asuragen, Inc | miRNAs DIFFERENTIALLY EXPRESSED IN LYMPH NODES FROM CANCER PATIENTS |
| EP2254668A4 (en) | 2008-02-28 | 2012-08-15 | Univ Ohio State Res Found | MICROARN SIGNATURES ASSOCIATED WITH HUMAN CHRONIC LYMPHOCYTIC LEUKEMIA (CLL) AND USES THEREOF |
| EP2112235A1 (en) | 2008-04-24 | 2009-10-28 | Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. | Compositions and methods for microRNA expression profiling of nasopharyngeal carcinoma |
| WO2009149539A1 (en) * | 2008-06-10 | 2009-12-17 | Université de Montréal | Enhancing antigen-specific cd8+ t cell response using irf-7 mrna |
| WO2010018563A2 (en) | 2008-08-12 | 2010-02-18 | Rosetta Genomics Ltd. | Compositions and methods for the prognosis of lymphoma |
| WO2010037408A1 (en) * | 2008-09-30 | 2010-04-08 | Curevac Gmbh | Composition comprising a complexed (m)rna and a naked mrna for providing or enhancing an immunostimulatory response in a mammal and uses thereof |
| CN102439169B (zh) | 2008-11-13 | 2014-11-19 | 复旦大学 | 用于结肠直肠癌的微rna表达谱分析的组合物和方法 |
| US20120053224A1 (en) | 2008-12-10 | 2012-03-01 | Universitat Regensburg | Compositions and methods for micro-rna expression profiling of cancer stem cells |
| CA2761411A1 (en) | 2009-05-08 | 2010-11-11 | The Ohio State University Research Foundation | Microrna expression profiling and targeting in chronic obstructive pulmonary disease (copd) lung tissue and methods of use thereof |
| SG10201912450XA (en) | 2009-06-10 | 2020-03-30 | Arbutus Biopharma Corp | Improved lipid formulation |
| WO2011076142A1 (en) | 2009-12-24 | 2011-06-30 | Fudan University | Compositions and methods for microrna expession profiling in plasma of colorectal cancer |
| WO2011076143A1 (en) | 2009-12-24 | 2011-06-30 | Fudan University | Compositions and methods for microrna expression profiling of lung cancer |
| EP2341145A1 (en) | 2009-12-30 | 2011-07-06 | febit holding GmbH | miRNA fingerprint in the diagnosis of diseases |
| WO2011094683A2 (en) | 2010-01-29 | 2011-08-04 | H. Lee Moffitt Cancer Center And Research Institute, Inc. | Method of identifying myelodysplastic syndromes |
| EP2354246A1 (en) | 2010-02-05 | 2011-08-10 | febit holding GmbH | miRNA in the diagnosis of ovarian cancer |
| WO2011113030A2 (en) | 2010-03-11 | 2011-09-15 | H.Lee Moffitt Cancer Center & Research Institute | Human cancer micro-rna expression profiles predictive of chemo-response |
| WO2011157294A1 (en) | 2010-06-16 | 2011-12-22 | Universita' Degli Studi Di Padova | Compositions for use in treating or preventing cancer, breast cancer, lung cancer, ovarian cancer, metastasis, heart failure, cardiac remodelling, dilated cardiomyopathy, autoimmune diseases, or diseases or disorders related thereto |
| EP4108671B1 (en) | 2010-10-01 | 2024-11-20 | ModernaTX, Inc. | Modified nucleosides, nucleotides, and nucleic acids, and uses thereof |
| HUE036148T2 (hu) * | 2010-10-26 | 2018-06-28 | Univ Friedrich Alexander Er | Az NFkB jelátviteli útvonalukban módosított dendritikus sejtek |
| CA2824526C (en) | 2011-01-11 | 2020-07-07 | Alnylam Pharmaceuticals, Inc. | Pegylated lipids and their use for drug delivery |
| US9085631B2 (en) | 2011-04-08 | 2015-07-21 | Nov Vac APS | Proteins and nucleic acids useful in vaccines targeting Staphylococcus aureus |
| WO2012151212A1 (en) | 2011-05-01 | 2012-11-08 | University Of Rochester | Multifocal hepatocellular carcinoma microrna expression patterns and uses thereof |
| EP2944961A1 (en) | 2011-05-06 | 2015-11-18 | XenTech | Markers for cancer prognosis and therapy and methods of use |
| US8691750B2 (en) | 2011-05-17 | 2014-04-08 | Axolabs Gmbh | Lipids and compositions for intracellular delivery of biologically active compounds |
| EP3336082B1 (en) | 2011-06-08 | 2020-04-15 | Translate Bio, Inc. | Cleavable lipids |
| WO2013011378A1 (en) | 2011-07-15 | 2013-01-24 | Leo Pharma A/S | Diagnostic microrna profiling in cutaneous t-cell lymphoma (ctcl) |
| US20150080243A1 (en) | 2011-09-01 | 2015-03-19 | Allegro Diagnostics Corp. | Methods and compositions for detecting cancer based on mirna expression profiles |
| US20140243240A1 (en) | 2011-10-26 | 2014-08-28 | Georgetown University | microRNA EXPRESSION PROFILING OF THYROID CANCER |
| US9061063B2 (en) | 2011-12-07 | 2015-06-23 | Alnylam Pharmaceuticals, Inc. | Biodegradable lipids for the delivery of active agents |
| WO2013103659A1 (en) | 2012-01-04 | 2013-07-11 | Board Of Supervisors Of Louisiana State University And Agricultural And Mechanical College | Stabilizing rna by incorporating chain-terminating nucleosides at the 3'-terminus |
| WO2013116126A1 (en) | 2012-02-01 | 2013-08-08 | Merck Sharp & Dohme Corp. | Novel low molecular weight, biodegradable cationic lipids for oligonucleotide delivery |
| US9265820B2 (en) | 2012-03-05 | 2016-02-23 | University Of Maryland, Baltimore | Multivalent vaccine protection from Staphylococcus aureus infection |
| WO2013151663A1 (en) * | 2012-04-02 | 2013-10-10 | modeRNA Therapeutics | Modified polynucleotides for the production of membrane proteins |
| US10093701B2 (en) * | 2012-09-07 | 2018-10-09 | University Of Miami | Fusion proteins for promoting an immune response, nucleic acids encoding same, and methods of making and use thereof |
| PT2922554T (pt) | 2012-11-26 | 2022-06-28 | Modernatx Inc | Arn modificado nas porções terminais |
| EP2931319B1 (en) | 2012-12-13 | 2019-08-21 | ModernaTX, Inc. | Modified nucleic acid molecules and uses thereof |
| JP2016504050A (ja) | 2013-01-17 | 2016-02-12 | モデルナ セラピューティクス インコーポレイテッドＭｏｄｅｒｎａ Ｔｈｅｒａｐｅｕｔｉｃｓ，Ｉｎｃ． | 細胞表現型の改変のためのシグナルセンサーポリヌクレオチド |
| US20160022840A1 (en) | 2013-03-09 | 2016-01-28 | Moderna Therapeutics, Inc. | Heterologous untranslated regions for mrna |
| US20160024181A1 (en) | 2013-03-13 | 2016-01-28 | Moderna Therapeutics, Inc. | Long-lived polynucleotide molecules |
| ES3012932T3 (en) | 2013-12-03 | 2025-04-10 | Evaxion Biotech As | Proteins and nucleic acids useful in vaccines targeting staphylococcus aureus |
| US10821175B2 (en) | 2014-02-25 | 2020-11-03 | Merck Sharp & Dohme Corp. | Lipid nanoparticle vaccine adjuvants and antigen delivery systems |
| PT3134131T (pt) * | 2014-04-23 | 2022-03-24 | Modernatx Inc | Vacinas de ácidos nucleicos |
| EP3140320B1 (en) | 2014-05-06 | 2018-12-26 | Targovax Asa | Peptide vaccine comprising mutant ras peptide and chemotherapeutic agent |
| LT3766916T (lt) | 2014-06-25 | 2023-01-10 | Acuitas Therapeutics Inc. | Nauji lipidai ir lipidų nanodalelių kompozicijos, skirtos nukleorūgščių tiekimui |
| TWI739740B (zh) * | 2015-04-22 | 2021-09-21 | 德商奎爾法克股份有限公司 | 用於治療腫瘤疾病之含有ｒｎａ的組成物 |
| JP2018526321A (ja) * | 2015-04-27 | 2018-09-13 | ザ・トラステイーズ・オブ・ザ・ユニバーシテイ・オブ・ペンシルベニア | 適応免疫応答を誘導するためのヌクレオシド修飾ｒｎａ |
| EP3328394A4 (en) * | 2015-07-30 | 2019-03-13 | ModernaTX, Inc. | CONCATEMEE peptide epitope RNAs |
| PL3368507T3 (pl) | 2015-10-28 | 2023-03-27 | Acuitas Therapeutics Inc. | Nowe preparaty lipidów i nanocząstek lipidowych do dostarczania kwasów nukleinowych |
-
2017
- 2017-10-26 EP EP17808634.4A patent/EP3532070A1/en not_active Withdrawn
- 2017-10-26 BR BR112019008369A patent/BR112019008369A2/pt not_active Application Discontinuation
- 2017-10-26 CN CN201780080846.2A patent/CN110402145A/zh active Pending
- 2017-10-26 KR KR1020197014935A patent/KR20190086681A/ko not_active Withdrawn
- 2017-10-26 JP JP2019522512A patent/JP2019532657A/ja active Pending
- 2017-10-26 RU RU2019116006A patent/RU2765874C2/ru active
- 2017-10-26 MX MX2019004810A patent/MX2019004810A/es unknown
- 2017-10-26 WO PCT/US2017/058585 patent/WO2018081459A1/en not_active Ceased
- 2017-10-26 AU AU2017347837A patent/AU2017347837A1/en not_active Abandoned
- 2017-10-26 SG SG11201903674YA patent/SG11201903674YA/en unknown
- 2017-10-26 CA CA3042015A patent/CA3042015A1/en active Pending
-
2018
- 2018-06-01 US US15/995,519 patent/US20180311343A1/en not_active Abandoned
-
2019
- 2019-04-24 IL IL266222A patent/IL266222A/en unknown
- 2019-11-01 US US16/671,921 patent/US20200261572A1/en not_active Abandoned
-
2022
- 2022-09-09 JP JP2022143786A patent/JP2022184924A/ja active Pending
-
2024
- 2024-06-27 US US18/756,934 patent/US20250170235A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2019532657A5 (enExample) | ||
| Wang et al. | Novel exosome-targeted T-cell-based vaccine counteracts T-cell anergy and converts CTL exhaustion in chronic infection via CD40L signaling through the mTORC1 pathway | |
| EP2127671B1 (en) | Therapeutic agent for cancer | |
| RU2019116006A (ru) | Матричные рибонуклеиновые кислоты для усиления иммунных ответов и способы их применения | |
| US20220241428A1 (en) | Macrophage specific engager compositions and methods of use thereof | |
| US20250345417A1 (en) | Compositions and methods for treatment of melanoma | |
| CN109045289A (zh) | 疫苗接种和抑制pd-1途径的组合 | |
| AU2004266034B2 (en) | In vivo targeting of dendritic cells | |
| US20250312428A1 (en) | Heterologous Prime Boost Vaccine | |
| JP2022533717A (ja) | 卵巣癌のための治療用ｒｎａ | |
| WO2024163465A1 (en) | Epstein-barr virus mrna vaccines | |
| TW202245808A (zh) | 用於治療癌症之治療性ｒｎａ | |
| BR112021001992A2 (pt) | efeito adjuvante do agonista tlr1/2 diprovocim sinergiza com anticorpos inibidores de checkpoint para eliminar doença | |
| CN118450902A (zh) | 诺如病毒疫苗及使用方法 | |
| Viehl et al. | A Tat Fusion Protein–Based Tumor Vaccine for Breast Cancer | |
| WO2024131833A1 (en) | Mrna-based hpv+ cancer vaccines, and uses thereof | |
| US20240115675A1 (en) | Method of treating a tumor with a combination of an il-7 protein and a nucleotide vaccine | |
| CN118369111A (zh) | 单纯疱疹病毒mRNA疫苗 | |
| US20250000971A1 (en) | Tlr4 agonist for modulating immune response | |
| US20250041278A1 (en) | Tlr8 agonist for modulating immune response | |
| US20250302955A1 (en) | Individualized cancer epitopes and methods of using the same | |
| JP7668549B2 (ja) | がん免疫療法におけるａｓｃスペック | |
| RU2785954C2 (ru) | Конструкты т-клеточного рецептора и их применение | |
| US20220305099A1 (en) | Methods for inducing an immune response against neoantigens | |
| TW202241463A (zh) | 對於細胞激素蛋白之治療時程 |